OSTEOARTHRITIS
Salmon calcitonin appears ineffective in the management of knee OA treatment in 2 RCTs
Osteoarthritis Cartilage. 2015 Apr;23(4):532-43.Two randomized control trials, with a combined 2206 patients, studied the effects of salmon calcitonin (sCT) in patients with symptomatic knee osteoarthritis. Changes in joint space width, pain, function, and safety were evaluated over a 24 month period after treatment began. The results of these trials indicated that salmon calcitonin did not have an effect on joint space width in comparison to placebo and that this treatment was unable to provide reproducible benefits for patient pain and function. The use of salmon calcitonin also resulted in an increased incidence of mild to moderate adverse events.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
